1. |
Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement [J]. Cell, 1985; 42(2)∶581.
|
2. |
Pasini B, Hofstra RM, Yin L,et al.The physical map of the human RET protooncogene [J]. Oncogene, 1995; 11(9)∶1737.
|
3. |
Durbec P, MarcosGutierrez CV, Kilkenny, et al.GDNF signalling through the Ret receptor tyrosine kinase [J]. Nature, 1996; 381(6585)∶789.
|
4. |
Besset V, Scott RP, Ibanez CF.Signaling complexes and proteinprotein interactions involved in the activation of the Ras and phosphatidylinositol 3kinase pathways by the cRet receptor tyrosine kinase [J]. J Biol Chem, 2000; 275(50)∶39159.
|
5. |
De Vita G, Melillo RM, Carlomagno F, et al. Tyrosine 1062 RETMEN2A mediates activation of Akt (protein kinase B) and mitogenactivated protein kinase pathways leading to PC12 cell survival [J]. Cancer Res, 2000; 60(14)∶3727.
|
6. |
Hayashi H, Ichihara M, Iwashita T, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell linederived neurotrophic factor [J]. Oncogene, 2000; 19(39)∶4469.
|
7. |
Alberti L, Borrello MG, Ghizzoni S, et al.Grb2 binding to the different isoforms of Ret tyrosine kinase [J]. Oncogene, 1998; 17(9)∶1079.
|
8. |
Arighi E, Alberti L, Torriti F, et al. Identification of Shc docking site on Ret tyrosine kinase [J]. Oncogene, 1997; 14(7)∶773.
|
9. |
Mercalli E, Ghizzoni S, Arighi E, et al.Key role of shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein [J]. Oncogene, 2001; 20(27)∶3475.
|
10. |
Musholt TJ, Musholt PB, Khaladj N, et al.Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma [J]. Surgery, 2000; 128(6)∶984.
|
11. |
Roque L, Nunes VM, Ribeiro C, et al.Karyotypic charaterization of papillary thyroid carcinoma [J]. Cancer, 2001; 92(10)∶2529.
|
12. |
Rabes HM.Gene rearrangements in radiationinduced thyroid carcinogenesis [J]. Med Pediatr Oncol, 2001; 36(5)∶574.
|
13. |
Sheils OM, O’leary JJ, Sweeney EC, et al.Assessment of ret/PTC1 rearrange ments in neoplastic thyroid tissue using TaqMan RTPCR [J]. J Pathol, 2000; 192(1)∶32.
|
14. |
Mai KT, Vaccani JP, Thomas J, et al. Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasis [J]. Thyroid, 2001; 11(9)∶859.
|
15. |
Basolo F, Molinaro E, Agate L, et al.RET protein expression has no prognostic impact on the longterm outcome of papillary thyroid carcinoma [J]. Eur J Endocrinol, 2001; 145(5)∶599.
|
16. |
Salvatore G, Nagata S, Billaud M, et al. Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase [J]. Biochem Biophys Res Commun, 2002; 294(4)∶813.
|
17. |
Hennige AM, Lammers R, Hoppner W, et al.Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1 [J]. Endocrinology, 2001; 142(10)∶4441.
|
18. |
Carlomagno F, Vitagliano D, Guida T, et al.The kinase inhibitor PP1 blocks tumor igenesis induced by RET oncogenes [J].Cancer Res, 2002; 62(4)∶1077.
|